Ann: MXC 100 Patient Milestone in Aus, Onboards Tetra Health, page-40

MM will work in Epilipsy, of that, I have no doubt. Talking to the Dr's that prescribe Medical Cannabis in Australia the benefits are simply unmatched by "pharma" medicines. I have personally seen the benefits in two children with Epilepsy. It is nothing short of amazing. (As a side note, the flow on effect for one family, and the Australian Economy was huge, Both Mum and Dad are off their depression and Anxiety meds as they now see a bright future for their children (that is all a parent truly wants), Mum has returned to work part time paying taxes rather than collecting benefits, and they are now planning their first holiday to the gold coast as a family - Tourism Dollars.

Having said that, the CannEpil question specifically is a little more complicated IMHO.

Being what MGC hopes will be a proprietary strain/combo that enables MGC to charge appropriately. Obviously, Clinical Trials can fail - it happens, assuming we pass through the clinical trial phase, the pressure point will be in distinguishing its benefit over other common MM products that are and will be available for what may be cheaper prices than CannEpil and then educating the medical profession to accept that a) MM has a place in the treatment of children specifically (Adults seem not to be as much of a concern to Dr's) and b) CannEpil is the Gold Standard to be used. In essence, I see it having the same issue as any other pharmaceutical launch product that claims to have a better patient outcome than existing medication BUT with the added hurdle that exists in some countries of regulatory red tape, Doctor caution and cost that is not covered by PBS at this stage (in Australia drugs are heavily subsidised by the Govt if they are on the PBS for non Australian readers)

Long story short, a lot of new drugs fail to gain market traction for a variety of reasons, CannEpil is no different in that regard with a few added regulatory hurdles.

If the MGC management can address these issues it will be a winner. Whilst not entirely focused on Children, I believe the price will potentially be the smallest issue if the drug works, parents will do anything to give their children a good life, in most cases, but it has to work and at the moment it has to work significantly better than cheaper alternatives because of the price I expect they will charge to recover R & D.